Hiba Z Ahmed1, Yuan Liu2, Kelli O'Connell3, Maaz Z Ahmed4, Richard J Cassidy5, Theresa W Gillespie6, Pretesh Patel5, Rathi N Pillai7, Madhusmita Behera7, Conor E Steuer7, Taofeek K Owonikoko7, Suresh S Ramalingam7, Walter J Curran5, Kristin A Higgins8. 1. Emory University School of Medicine, Atlanta, GA; Emory University Rollins School of Public Health, Atlanta, GA. 2. Department of Biostatistics and Bioinformatics, Winship Cancer Institute, Emory University, Atlanta, GA. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Emory University School of Medicine, Atlanta, GA. 5. Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA. 6. Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA. 7. Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA. 8. Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA. Electronic address: kristin.higgins@emory.edu.
Abstract
BACKGROUND: Current evidence-based guideline-concordant care (GCC) for locally advanced non-small-cell lung cancer (NSCLC) patients with good performance status is concurrent chemoradiation. In this study we evaluated factors associated with lack of GCC and its effects on overall survival (OS). PATIENTS AND METHODS: Unresectable stage III NSCLC patients, diagnosed from 2005 to 2013 with a Charlson-Deyo score of 0, were identified from the National Cancer Database. Primary outcomes were receipt of GCC, defined as concurrent chemoradiation (thoracic radiotherapy, starting within 2 weeks of chemotherapy, to at least 60 Gy), and OS. Multivariable logistic regression modeling identified variables associated with non-GCC. Cox proportional hazard modeling was used to examine OS. RESULTS: Twenty-three percent of patients (n = 10,476) received GCC. Uninsured patients were more likely to receive non-GCC (odds ratio [OR], 1.54; P < .001) compared with privately insured patients. Other groups with greater odds of receiving non-GCC included: patients treated in the western, southern, or northeastern United States (ORs, 1.39, 1.37, and 1.19, respectively; all Ps < .001) compared with the Midwest; adenocarcinoma histology (OR, 1.48; P < .001) compared with squamous cell carcinoma; and women (OR, 1.08; P = .002). Those who received non-GCC had higher death rates compared with those who received GCC (hazard ratio [HR], 1.42; P < .001). The uninsured (HR, 1.53; P < .001), patients treated in the western, southern, or northeastern United States (HRs, 1.56, 1.41, and 1.34, respectively; P < .001), adenocarcinomas (HR, 1.39; P < .001), and women (HR, 1.44; P < .001) also all had lower OS for non-GCC versus GCC. CONCLUSION: Socioeconomic factors, including lack of insurance and geography, are associated with non-GCC. Patient- and disease-specific factors, including increasing adenocarcinoma histology and sex, are also associated with non-GCC. Non-GCC diminishes OS.
BACKGROUND: Current evidence-based guideline-concordant care (GCC) for locally advanced non-small-cell lung cancer (NSCLC) patients with good performance status is concurrent chemoradiation. In this study we evaluated factors associated with lack of GCC and its effects on overall survival (OS). PATIENTS AND METHODS: Unresectable stage III NSCLCpatients, diagnosed from 2005 to 2013 with a Charlson-Deyo score of 0, were identified from the National Cancer Database. Primary outcomes were receipt of GCC, defined as concurrent chemoradiation (thoracic radiotherapy, starting within 2 weeks of chemotherapy, to at least 60 Gy), and OS. Multivariable logistic regression modeling identified variables associated with non-GCC. Cox proportional hazard modeling was used to examine OS. RESULTS: Twenty-three percent of patients (n = 10,476) received GCC. Uninsured patients were more likely to receive non-GCC (odds ratio [OR], 1.54; P < .001) compared with privately insured patients. Other groups with greater odds of receiving non-GCC included: patients treated in the western, southern, or northeastern United States (ORs, 1.39, 1.37, and 1.19, respectively; all Ps < .001) compared with the Midwest; adenocarcinoma histology (OR, 1.48; P < .001) compared with squamous cell carcinoma; and women (OR, 1.08; P = .002). Those who received non-GCC had higher death rates compared with those who received GCC (hazard ratio [HR], 1.42; P < .001). The uninsured (HR, 1.53; P < .001), patients treated in the western, southern, or northeastern United States (HRs, 1.56, 1.41, and 1.34, respectively; P < .001), adenocarcinomas (HR, 1.39; P < .001), and women (HR, 1.44; P < .001) also all had lower OS for non-GCC versus GCC. CONCLUSION: Socioeconomic factors, including lack of insurance and geography, are associated with non-GCC. Patient- and disease-specific factors, including increasing adenocarcinoma histology and sex, are also associated with non-GCC. Non-GCC diminishes OS.
Authors: Norma E Farrow; Selena J An; Paul J Speicher; David H Harpole; Thomas A D'Amico; Jacob A Klapper; Matthew G Hartwig; Betty C Tong Journal: J Thorac Cardiovasc Surg Date: 2019-11-13 Impact factor: 5.209
Authors: Sophia Scharl; Tim Sprötge; Michael Gerken; Anton Scharl; Olaf Ortmann; Oliver Kölbl; Monika Klinkhammer-Schalke; Thomas Papathemelis Journal: J Cancer Res Clin Oncol Date: 2022-10-14 Impact factor: 4.322
Authors: Jennifer C Wang; Li Ding; Elizabeth A David; Scott M Atay; Sean C Wightman; P Michael McFadden; Takashi Harano; Anthony W Kim Journal: JTCVS Open Date: 2022-02-15
Authors: Umit Tapan; Kimberley S Mak; Michelle H Lee; Muhammad Mustafa Qureshi; Kei Suzuki; Peter Everett Journal: J Thorac Dis Date: 2022-08 Impact factor: 3.005
Authors: Susan Y Wu; Ann A Lazar; Matthew A Gubens; Collin M Blakely; Alexander R Gottschalk; David M Jablons; Thierry M Jahan; Victoria E H Wang; Taylor L Dunbar; Melisa L Wong; Jason W Chan; William Guthrie; Jeff Belkora; Sue S Yom Journal: JAMA Netw Open Date: 2020-09-01
Authors: Rolando Sanchez; Yunshu Zhou; Mary S Vaughan Sarrazin; Peter J Kaboli; Mary Charlton; Richard M Hoffman Journal: J Rural Health Date: 2020-05-30 Impact factor: 4.333